NASDAQ:RYTM

Rhythm Pharmaceuticals Competitors

$20.75
+0.10 (+0.48 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.20
Now: $20.75
$21.72
50-Day Range
$20.25
MA: $24.10
$26.84
52-Week Range
$16.16
Now: $20.75
$43.26
Volume321,445 shs
Average Volume483,266 shs
Market Capitalization$1.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.57

Competitors

Rhythm Pharmaceuticals (NASDAQ:RYTM) Vs. ARNA, EBS, IMAB, TPTX, AGIO, and APLS

Should you be buying RYTM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Rhythm Pharmaceuticals, including Arena Pharmaceuticals (ARNA), Emergent BioSolutions (EBS), I-Mab (IMAB), Turning Point Therapeutics (TPTX), Agios Pharmaceuticals (AGIO), and Apellis Pharmaceuticals (APLS).

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Volatility and Risk

Rhythm Pharmaceuticals has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Rhythm Pharmaceuticals and Arena Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rhythm Pharmaceuticals01502.83
Arena Pharmaceuticals001503.00

Rhythm Pharmaceuticals currently has a consensus target price of $50.6667, indicating a potential upside of 144.18%. Arena Pharmaceuticals has a consensus target price of $92.80, indicating a potential upside of 37.20%. Given Rhythm Pharmaceuticals' higher possible upside, research analysts plainly believe Rhythm Pharmaceuticals is more favorable than Arena Pharmaceuticals.

Insider & Institutional Ownership

88.4% of Rhythm Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 9.5% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rhythm Pharmaceuticals and Arena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm PharmaceuticalsN/AN/A$-140,730,000.00($3.86)-5.38
Arena Pharmaceuticals$806.43 million5.06$397.55 million$7.698.80

Arena Pharmaceuticals has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Rhythm Pharmaceuticals and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rhythm PharmaceuticalsN/A-55.21%-50.73%
Arena PharmaceuticalsN/A-33.17%-30.41%

Summary

Arena Pharmaceuticals beats Rhythm Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Emergent BioSolutions (NYSE:EBS) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Earnings & Valuation

This table compares Emergent BioSolutions and Rhythm Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.11 billion3.59$54.50 million$2.9125.59
Rhythm PharmaceuticalsN/AN/A$-140,730,000.00($3.86)-5.38

Emergent BioSolutions has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Emergent BioSolutions has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Emergent BioSolutions and Rhythm Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emergent BioSolutions02502.71
Rhythm Pharmaceuticals01502.83

Emergent BioSolutions currently has a consensus price target of $113.6667, indicating a potential upside of 52.63%. Rhythm Pharmaceuticals has a consensus price target of $50.6667, indicating a potential upside of 144.18%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Emergent BioSolutions.

Profitability

This table compares Emergent BioSolutions and Rhythm Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emergent BioSolutions12.50%26.68%12.70%
Rhythm PharmaceuticalsN/A-55.21%-50.73%

Insider and Institutional Ownership

80.2% of Emergent BioSolutions shares are owned by institutional investors. Comparatively, 88.4% of Rhythm Pharmaceuticals shares are owned by institutional investors. 14.1% of Emergent BioSolutions shares are owned by insiders. Comparatively, 9.5% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Emergent BioSolutions beats Rhythm Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Rhythm Pharmaceuticals (NASDAQ:RYTM) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Earnings & Valuation

This table compares Rhythm Pharmaceuticals and I-Mab's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm PharmaceuticalsN/AN/A$-140,730,000.00($3.86)-5.38
I-Mab$4.31 million919.62$-208,560,000.00($28.90)-1.91

Rhythm Pharmaceuticals has higher earnings, but lower revenue than I-Mab. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Rhythm Pharmaceuticals and I-Mab, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rhythm Pharmaceuticals01502.83
I-Mab00403.00

Rhythm Pharmaceuticals presently has a consensus target price of $50.6667, indicating a potential upside of 144.18%. I-Mab has a consensus target price of $70.00, indicating a potential upside of 27.06%. Given Rhythm Pharmaceuticals' higher probable upside, equities analysts plainly believe Rhythm Pharmaceuticals is more favorable than I-Mab.

Profitability

This table compares Rhythm Pharmaceuticals and I-Mab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rhythm PharmaceuticalsN/A-55.21%-50.73%
I-MabN/AN/AN/A

Insider & Institutional Ownership

88.4% of Rhythm Pharmaceuticals shares are held by institutional investors. Comparatively, 16.6% of I-Mab shares are held by institutional investors. 9.5% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Rhythm Pharmaceuticals beats I-Mab on 6 of the 11 factors compared between the two stocks.

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Earnings & Valuation

This table compares Rhythm Pharmaceuticals and Turning Point Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm PharmaceuticalsN/AN/A$-140,730,000.00($3.86)-5.38
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-25.38

Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Rhythm Pharmaceuticals has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Rhythm Pharmaceuticals and Turning Point Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rhythm Pharmaceuticals01502.83
Turning Point Therapeutics00703.00

Rhythm Pharmaceuticals presently has a consensus target price of $50.6667, indicating a potential upside of 144.18%. Turning Point Therapeutics has a consensus target price of $153.7143, indicating a potential upside of 102.52%. Given Rhythm Pharmaceuticals' higher probable upside, equities analysts plainly believe Rhythm Pharmaceuticals is more favorable than Turning Point Therapeutics.

Profitability

This table compares Rhythm Pharmaceuticals and Turning Point Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rhythm PharmaceuticalsN/A-55.21%-50.73%
Turning Point TherapeuticsN/A-23.81%-23.08%

Insider & Institutional Ownership

88.4% of Rhythm Pharmaceuticals shares are held by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are held by institutional investors. 9.5% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Turning Point Therapeutics beats Rhythm Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Insider & Institutional Ownership

88.4% of Rhythm Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are held by institutional investors. 9.5% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 3.2% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Rhythm Pharmaceuticals has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Rhythm Pharmaceuticals and Agios Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rhythm Pharmaceuticals01502.83
Agios Pharmaceuticals03702.70

Rhythm Pharmaceuticals presently has a consensus target price of $50.6667, indicating a potential upside of 144.18%. Agios Pharmaceuticals has a consensus target price of $64.6364, indicating a potential upside of 21.13%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Rhythm Pharmaceuticals is more favorable than Agios Pharmaceuticals.

Profitability

This table compares Rhythm Pharmaceuticals and Agios Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rhythm PharmaceuticalsN/A-55.21%-50.73%
Agios Pharmaceuticals-170.65%-57.63%-37.15%

Earnings & Valuation

This table compares Rhythm Pharmaceuticals and Agios Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm PharmaceuticalsN/AN/A$-140,730,000.00($3.86)-5.38
Agios Pharmaceuticals$117.91 million31.50$-411,470,000.00($6.86)-7.78

Rhythm Pharmaceuticals has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Rhythm Pharmaceuticals beats Agios Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Apellis Pharmaceuticals (NASDAQ:APLS) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Insider & Institutional Ownership

81.2% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 88.4% of Rhythm Pharmaceuticals shares are held by institutional investors. 9.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 9.5% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Apellis Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Apellis Pharmaceuticals and Rhythm Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apellis Pharmaceuticals031012.86
Rhythm Pharmaceuticals01502.83

Apellis Pharmaceuticals presently has a consensus target price of $124.6154, indicating a potential upside of 180.16%. Rhythm Pharmaceuticals has a consensus target price of $50.6667, indicating a potential upside of 144.18%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Apellis Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Profitability

This table compares Apellis Pharmaceuticals and Rhythm Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apellis PharmaceuticalsN/A-336.93%-78.28%
Rhythm PharmaceuticalsN/A-55.21%-50.73%

Valuation and Earnings

This table compares Apellis Pharmaceuticals and Rhythm Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.59
Rhythm PharmaceuticalsN/AN/A$-140,730,000.00($3.86)-5.38

Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


Rhythm Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.64+1.8%$4.08 billion$806.43 million-9.58Analyst Report
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$74.47+2.3%$3.97 billion$1.11 billion23.95Analyst Report
I-Mab logo
IMAB
I-Mab
1.4$55.09+9.9%$3.96 billion$4.31 million-1.91Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$75.90+1.4%$3.72 billionN/A-21.62Analyst Report
High Trading Volume
News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$53.36+2.4%$3.71 billion$117.91 million-10.82
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$44.48+5.0%$3.58 billionN/A-5.99News Coverage
LEGN
Legend Biotech
1.2$26.76+1.1%$3.53 billion$64.39 million0.00Decrease in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.14+2.4%$3.49 billion$114.62 million-7.72Analyst Report
News Coverage
Insmed logo
INSM
Insmed
1.2$33.02+4.1%$3.41 billion$136.47 million-12.70
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.28+3.2%$3.41 billion$339.08 million-12.37Analyst Report
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.90+1.2%$3.37 billion$306.98 million-6.85
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.34+0.3%$3.30 billion$36.13 million-70.66Unusual Options Activity
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$89.75+3.7%$3.25 billion$26.52 million-7.91
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$115.44+3.8%$3.12 billionN/A-57.43Insider Selling
News Coverage
Arvinas logo
ARVN
Arvinas
1.5$62.89+2.5%$3.07 billion$42.98 million-24.57News Coverage
Alkermes logo
ALKS
Alkermes
1.2$19.23+1.9%$3.06 billion$1.17 billion-41.80
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$69.43+1.7%$3.05 billion$421.03 million24.45Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.69+1.5%$2.99 billion$80.43 million108.05Decrease in Short Interest
Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.21+1.9%$2.82 billion$901.90 million-23.36
Organogenesis logo
ORGO
Organogenesis
1.0$21.90+3.7%$2.80 billion$260.98 million-365.00
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.80+0.6%$2.79 billion$644.77 million-10.39
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.95+2.9%$2.69 billion$306.49 million25.79
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.53+3.4%$2.69 billionN/A-23.92
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.96+5.5%$2.65 billion$25 million-9.19Insider Selling
News Coverage
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.98+6.7%$2.64 billion$182.24 million-8.68Analyst Upgrade
Gap Down
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$32.27+3.8%$2.61 billion$60,000.00-10.02
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$41.47+3.1%$2.58 billion$2.11 million-8.98Analyst Report
News Coverage
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$151.03+2.7%$2.51 billion$120.28 million-152.56Analyst Report
Decrease in Short Interest
News Coverage
Xencor logo
XNCR
Xencor
1.0$43.17+6.9%$2.50 billion$156.70 million-30.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$59.80+4.5%$2.40 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.64+1.3%$2.36 billion$33.94 million-89.03
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.21+2.3%$2.35 billion$15 million-17.39Unusual Options Activity
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.81+0.5%$2.18 billion$963.01 million13.61News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$27.83+3.6%$2.12 billion$23.90 million-17.29Analyst Report
Analyst Revision
News Coverage
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.17+1.3%$2.01 billion$410,000.00-6.12Analyst Report
News Coverage
Amarin logo
AMRN
Amarin
1.6$5.11+0.6%$2.01 billion$429.76 million-102.18News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.55+3.4%$2.00 billionN/A-19.91
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.80+5.3%$1.98 billion$103.54 million-19.40Insider Selling
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$63.93+2.6%$1.96 billionN/A-27.20Increase in Short Interest
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$120.94+4.4%$1.94 billionN/A-10.93
Kura Oncology logo
KURA
Kura Oncology
1.6$29.20+5.8%$1.93 billionN/A-17.91
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$47.01+2.9%$1.93 billionN/A0.00Analyst Report
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.65+1.7%$1.89 billion$34.51 million-17.65
MacroGenics logo
MGNX
MacroGenics
1.2$31.28+5.5%$1.88 billion$64.19 million-9.99Decrease in Short Interest
MORF
Morphic
1.3$55.98+3.0%$1.82 billion$16.98 million-35.88Insider Selling
Decrease in Short Interest
News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.99+0.1%$1.77 billion$14.87 million-14.18Increase in Short Interest
FibroGen logo
FGEN
FibroGen
1.8$19.26+2.4%$1.76 billion$256.58 million-7.38Analyst Report
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.82+1.0%$1.74 billion$1.63 billion14.20Analyst Report
Decrease in Short Interest
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.